As of 2014, a total of 452 clinical studies of peptide-based vaccines were registered with the US federal government clinical trials database. Of these, none have progressed to market, and only a small number (12) made it to phase III clinical trials; furthermore, of these phase III trials, none were for vaccines directed against infectious diseases. The lack of success of peptide vaccines against pathogenic infections is due to the fact that antibodies against a single epitope on a pathogen are rarely protective.

Question

Quizplus · Accepted Answer

Peptide-based vaccines have shown promise in various stages of clinical trials, including those targeting infectious diseases. The statement that none have progressed to market is inaccurate, as there have been developments and approvals in this area, albeit the progress might be slower or more complex compared to other vaccine types. The effectiveness of peptide vaccines can vary depending on the target disease and the design of the vaccine, including the choice of epitopes and how they are presented to the immune system.

As of 2014, a Total of 452 Clinical Studies of Peptide-Based